• 2000: The Neme gene responsible for the desease and the most frequent anomaly in the gene, the
  re-arrangement (80% cases) are identified thanks to international scientific collaboration including France (INSERM, CNRS, Institut Pasteur), Germany, Great Britain, Italyand the USA. A publication on the subject is made on 25 May 2000.
  
• 2001: The PCR test showing the anomaly in the Nemo gene is elaborated. Test of  the non activation of the X chromosome in women with IP.
  
• 2004: A prenatal diagnosis is elaborated and used under the control of a scientific council.
  
• 2006:  A  pre-implant diagnosis is elaborated which makes it possible to detect the decease in the embryo, in vitro, before it is implanted in the uterus.

Incontinentia Pigmenti could act as a model for other deseases. Indeed the Nemo gene is known to activate the main cell tracks involved in growth, immune and inflammatory responses and a number of other functions. By studying those, researchers hope to get a better understanding of the biological processes controlled by the gene and how the dysfunction of Nemo leads to the various clinical symptoms of the desease.